Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.

Purpose: To evaluate clinical outcome(s) and complication(s) of topical bevacizumab (avastin) in patients with impending recurrent pterygium.

Patients And Methods: This prospective clinical trial included 54 consecutive patients (54 eyes), who underwent pterygium surgery with bare sclera and mitomycin, and who were diagnosed with impending recurrent pterygium. Of the 54 patients, 26 received eye drops containing bevacizumab (5 mg/ml) twice a day and betamethasone four times daily for 1 week.